Is there a medicine for GLP-1 nausea? Tradipitant, so far
Reviewed 15 sourcesPublished by PepVault
No medicine is approved for GLP-1 nausea yet. Tradipitant, a motion-sickness pill, cut vomiting after semaglutide in phase 3. What it does, and what helps now.

- Last reviewed
- Sources
- 15
- Questions
- 8
- Compounds
- 2
The short answer
Not yet: none is approved for GLP-1 nausea. The closest is tradipitant, an anti-vomiting pill already approved in the US as Nereus for vomiting caused by motion. In a phase 3 trial reported on October 27, 2026, it cut vomiting after a 1 mg semaglutide shot from 58.5% on placebo to 43.0%. Vanda plans to seek approval. Until then, a slow dose climb, smaller meals and fluids do the work.
Evidence: Two company-run, placebo-controlled trials in people given a single 1 mg semaglutide shot, reported by Vanda in press releases and not yet in a journal; FDA prescribing information for the motion-sickness approval and for Wegovy and Zepbound.

Is there a medicine for Ozempic or GLP-1 nausea yet?
Not one approved for it. As of November 20, 2026, the FDA has approved no medicine for the nausea or vomiting that GLP-1 shots such as Ozempic, Wegovy, Mounjaro and Zepbound can cause. Furthest along is tradipitant from Vanda Pharmaceuticals, already sold as Nereus, but only to prevent vomiting caused by motion, such as on a boat67. Vanda has finished two placebo-controlled trials in people given semaglutide, the medicine in Ozempic and Wegovy, calls both positive34, and plans to file for a GLP-1 approval5.
Today, GLP-1 nausea is handled the way the labels describe: a slow dose climb, a pause in that climb when a step is not tolerated, and plenty of fluids1213. Prescribers can also use general anti-sickness medicines case by case, as an expert panel suggests when nausea persists despite diet changes14. The last section of this guide sets those steps out.

What is tradipitant and how does it work?
Tradipitant is an NK1 receptor blocker, taken as a capsule. Substance P is a messenger chemical that helps trigger vomiting when it lands on NK1 receptors, docking points found along the vomiting pathway in the brainstem and the gut815. Tradipitant sits in those receptors so substance P cannot switch them on. Brain scans show it crosses into the brain and occupies its NK1 receptors; the label adds that the exact way it prevents vomiting is not fully worked out6.
It is the same class as aprepitant (Emend), an NK1 blocker approved for years to prevent the nausea and vomiting of cancer chemotherapy, used together with other anti-sickness drugs9. Tradipitant is a small molecule, not a peptide, and it does not touch the receptors that older anti-sickness drugs work on, such as serotonin, dopamine or histamine receptors6. Vanda licensed it from Eli Lilly in 201211.
What did the tradipitant GLP-1 trials find?
Both trials used the same hard test. Adults with overweight or obesity and no diabetes (in phase 2, none had used a GLP-1 before) took tradipitant or a dummy capsule twice a day for about two weeks, and got one 1 mg shot of semaglutide with no dose climb before it1234. Each kept a daily diary of vomiting and of nausea on a 0 to 5 scale12. The main measure: how many people vomited at least once in the week after the shot12.
| Measure | Phase 2 (2025) | Phase 3, Study 3601 (2026) |
|---|---|---|
| People analysed | 116 (58 per group)4 | 306 (142 tradipitant, 164 placebo)3 |
| Vomited at least once, tradipitant | 29.3%4 | 43.0%3 |
| Vomited at least once, placebo | 58.6%4 | 58.5%3 |
| Relative cut in vomiting | 50%4 | 27%3 |
| Vomiting plus a worst nausea score of 3 or more (0 to 5) | 22.4% vs 48.3%4 | 33.1% vs 50.6%3 |
| More than 10 vomiting episodes, a post hoc look | About 80% fewer3 | 2.8% vs 14.6%3 |
In phase 3 both prespecified results were statistically significant (p=0.006 for any vomiting, p=0.002 for vomiting with nausea)3. The bigger cuts in heavy vomiting came from analyses chosen after the data were in, which Vanda presents as supportive rather than proof3. Almost all vomiting in both groups happened by day 2 after the shot3. Vanda reported no new safety signals in either trial, and the results have not yet appeared in a journal as of November 20, 202634.
Does tradipitant stop the nausea or the vomiting?
Mainly the vomiting, on the evidence so far. On its motion-sickness boat trials, the approved label shows vomiting fell from 44% on placebo to 18 to 20% in one trial and from 38% to 10 to 18% in the other, while the worst nausea score was almost the same as placebo and the gap was not significant in either6. The approval reads that way too: "prevention of vomiting induced by motion", not nausea67.
The GLP-1 trials point the same way. Their main measure is vomiting, and Vanda's planned filing names the prevention of vomiting with GLP-1 therapy35. The phase 3 trial also measured each person's worst nausea score over the week on its own1, and Vanda's release gives no result for it3. So for someone whose problem is queasiness without vomiting, there is no trial answer yet.
How close is the trial to real life on a GLP-1?
Not very, by design. Wegovy's label reaches 1 mg only in weeks 9 to 12, after two four-week steps at 0.25 and 0.5 mg, and the climb exists to lower stomach side effects12. The trials gave 1 mg on day one, which Vanda calls a rigorous test with a strong trigger34. That is why more than half of the placebo group vomited within a week, against far lower rates over months of treatment on the labels1213:
| Setting | Vomiting on the drug | Vomiting on placebo |
|---|---|---|
| Tradipitant phase 3: one 1 mg semaglutide shot, no climb, 1 week | 43.0% with tradipitant3 | 58.5%3 |
| Wegovy 2.4 mg label: climb over 16 weeks, trials up to 68 weeks | 24%12 | 6%12 |
| Zepbound 15 mg label: climb up to 20 weeks, trials up to 72 weeks | 13%13 | 2%13 |
The rows count different people over different times, and the labels warn that rates across trials cannot be compared directly1213. The gap shows what the trial asks: whether tradipitant blunts a heavy first hit, not whether it helps three months into a slow climb. Vanda says a pooled analysis of drug levels across both trials supports use at ordinary doses, without numbers yet3. Only semaglutide was tested. Vanda expects the effect to carry to every GLP-1 because tradipitant acts in the brain's vomiting centre3; for tirzepatide that is untested.
What else has tradipitant been tested for?
| Use | What happened | When |
|---|---|---|
| Motion sickness | Two boat trials met their goal; FDA approved Nereus to prevent vomiting caused by motion in adults | Approved December 30, 202578 |
| Gastroparesis, a stomach that empties too slowly | Phase 2 met its nausea goal; the 12-week phase 3 in 201 adults missed its main goal (p=0.741)1011 | FDA declined to approve on September 18, 2024; Vanda is challenging that in court511 |
| Itch in atopic dermatitis (eczema) | Phase 3 (EPIONE) missed its main itch goal; a second phase 3 was put on hold11 | 2020; no longer in Vanda's pipeline list in October 20265 |
On the approved label, Nereus is a single 85 mg or 170 mg dose about an hour before travel, at most one dose a day, taken on an empty stomach6. Its most common side effects were sleepiness, headache and tiredness, each in 12% or fewer on the higher dose6. The label warns that it can affect driving, more so with other sedating medicines or with drugs that strongly block CYP3A4, one of the liver enzymes that clear it6. The GLP-1 trials gave it twice a day for about two weeks, 85 mg per dose in phase 214, a different schedule from the label; using it for GLP-1 sickness today would be off label, a prescriber's decision.
When could tradipitant be approved for GLP-1 vomiting?
Not before Vanda files and the FDA reviews the filing. In its quarterly report of October 29, 2026, Vanda said it intends to discuss the phase 3 results with the FDA and plans to submit a supplemental application, the filing that adds a new use to an approved medicine, for preventing vomiting with GLP-1 therapy5. Its release expects the FDA's feedback on that planned filing during 20273.
- The registry: the phase 3 record (NCT07446439), started March 27, 2026, still lists the status "recruiting", an estimated 280 people and an estimated primary completion of December 1, 2026; it was last updated on April 20, 2026, before the October results1. The release analysed 306, more than the registry's estimate, and the phase 2 record lists 124 enrolled against the 116 its release analysed24.
- A journal paper: not published as of November 20, 2026; when it is, this guide will add the nausea-only result and the side effects by group.
- The FDA: no filing or decision reported as of November 20, 2026. This section will carry the filing date and the decision when they come.
What helps with GLP-1 nausea right now?
Nausea is the most common side effect of these shots: on Wegovy 2.4 mg 44% reported it against 16% on placebo, on Zepbound 25 to 29% against 8%, and Zepbound's label notes most stomach effects came during the climb and decreased over time1213. The steps below come from the labels and an expert panel121314:
- Follow the climb your prescriber set; if a step is too rough, ask about staying on the lower dose longer: Wegovy's label tells prescribers to consider delaying the next step by four weeks12.
- Serve a smaller portion, eat slowly, and stop as soon as you feel full14.
- Choose plain, low-fat food, baked, grilled or boiled, over fatty or spicy food and rich sauces14.
- Stay upright after eating, and leave a gap before bed14.
- Sip fluids through the day, more on any day with vomiting or diarrhoea, since losing fluid can strain the kidneys121314.
- If nausea keeps coming back despite this, ask your prescriber about an anti-sickness medicine; the panel suggests considering one when nausea persists14.
Commonly reported: queasiness worst a day or two after the shot and after each step-up, fatty food losing its appeal, and sulphur-tasting burps after a heavy meal.
PepVault's side-effect log keeps each symptom with the compound, a severity from minimal to very severe, the date and a note, so you can show your prescriber which step and which days it hit. Log it in PepVault
Its dose reminders keep your weekly shot day steady, and the dose log keeps each shot with its date and the step-ups your prescriber set, as you enter them. Set reminders in PepVault
When to get help Both labels say to tell your healthcare provider right away about nausea, vomiting or diarrhoea that does not go away, and to drink fluids to lower the chance of dehydration1213.
Next: our guides to Ozempic and Wegovy side effects and to Mounjaro and Zepbound side effects give every label rate and how long nausea lasts.
Sources
- ClinicalTrials.gov NCT07446439. The Thetis Study: tradipitant on nausea and vomiting after GLP-1R agonist administration (VP-VLY-686-3601). Sponsor Vanda Pharmaceuticals. Record last updated April 20, 2026; read November 20, 2026. clinicaltrials.gov
- ClinicalTrials.gov NCT06804603. Proof-of-concept study of tradipitant on nausea and vomiting after GLP-1R agonist administration (VP-VLY-686-2601). Sponsor Vanda Pharmaceuticals. Completed October 6, 2025. clinicaltrials.gov
- Vanda Pharmaceuticals. Vanda Pharmaceuticals announces positive results from Study 3601 of NEREUS (tradipitant) for prevention of GLP-1-induced vomiting. Press release, PR Newswire, October 27, 2026 (not filed as an SEC exhibit; the October 28, 2026 Form 8-K, Exhibit 99.1, confirms the results were announced). prnewswire.com
- Vanda Pharmaceuticals. Vanda reports positive results for tradipitant in preventing GLP-1 induced nausea and vomiting. Press release, PR Newswire, November 17, 2025. prnewswire.com
- Vanda Pharmaceuticals Inc. Form 10-Q for the quarter ended September 30, 2026, filed with the SEC October 29, 2026. sec.gov
- NEREUS (tradipitant) capsules prescribing information, DailyMed (SPL version 5; label effective September 1, 2026, published on DailyMed October 19, 2026). Sections 1, 2, 5, 6, 7, 12 and 14. dailymed.nlm.nih.gov
- US Food and Drug Administration. NDA 220152 (NEREUS, tradipitant) approval letter, December 30, 2025. Drugs@FDA. accessdata.fda.gov
- Vanda Pharmaceuticals. Vanda announces FDA approval of NEREUS (tradipitant) for the prevention of vomiting induced by motion. Press release, December 30, 2025 (Form 8-K, Exhibit 99.1). sec.gov
- EMEND (aprepitant) capsules and oral suspension prescribing information, DailyMed (published November 6, 2026). Sections 1 and 12.1. dailymed.nlm.nih.gov
- Carlin JL et al. The efficacy of tradipitant in patients with diabetic and idiopathic gastroparesis in a phase 3 randomized placebo-controlled clinical trial. Clin Gastroenterol Hepatol. 2024. PubMed 38237696
- Vanda Pharmaceuticals Inc. Form 10-K for the year ended December 31, 2025, filed with the SEC February 12, 2026. sec.gov
- WEGOVY (semaglutide) injection and tablets prescribing information, DailyMed (SPL version 19; label updated June 18, 2026, published on DailyMed June 30, 2026). Sections 2, 5, 6.1 (Table 3) and the Medication Guide. dailymed.nlm.nih.gov
- ZEPBOUND (tirzepatide) injection prescribing information, DailyMed (SPL version 40; label updated August 28, 2026, published on DailyMed September 2, 2026). Sections 2, 5, 6.1 and the Medication Guide. dailymed.nlm.nih.gov
- Gorgojo-Martínez JJ et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2023. PubMed 36614945
- Polymeropoulos VM et al. Motion Syros: tradipitant effective in the treatment of motion sickness; a multicenter, randomized, double-blind, placebo-controlled study. Front Neurol. 2025. PubMed 40103934
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.